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Bone marrow-derived cells (BMDCs) are capable of migrating across the blood–brain 
barrier (BBB) and accumulating in the central nervous system (CNS) when transplanted 
into recipients conditioned with whole-body irradiation or chemotherapy. We used the 
chemotherapeutic agents busulfan and treosulfan to condition recipient mice for trans-
plantation with bone marrow (BM) cells isolated from donor mice ubiquitously expressing 
green fluorescent protein. We attempted to increase the accumulation of BMDCs in the 
CNS by mobilization of BMDCs using either, or both, granulocyte colony-stimulating 
factor (GCSF) or plerixafor (AMD3100). We also used several concentrations of busul-
fan. We hypothesized that higher concentrations of busulfan and BMDC mobilization 
would increase numbers of GFP+ cells in the CNS. The doses of busulfan employed 
(60–125  mg/kg) all resulted in high levels of sustained chimerism (>85% 1  year 
post-transplant) in both the blood and BM of wild-type (WT) mice and an amyotrophic 
lateral sclerosis (ALS) mouse model. Moreover, cells accumulated within the CNS in a 
dose-, time-, and disease-dependent manner. Conditioning with the hydrophilic busulfan 
analog treosulfan, which is unable to cross the BBB efficiently, also resulted in a high 
degree of BM chimerism. However, few GFP+ BMDCs were found within the CNS of WT 
or ALS mice of treosulfan-conditioned mice. Mobilization of BMDCs into the circulation 
using GCSF and/or AMD3100 did not lead to increased accumulation of GFP+ BMDCs 
within the CNS of WT or ALS mice. Weekly analysis of BMDC accumulation revealed 
that BMDCs accumulated more rapidly and to a greater extent in the CNS of ALS mice 
conditioned with a high dose (125 mg/kg) of busulfan compared to a lower dose (80 mg/
kg). The number of GFP+ BMDCs in the CNS labeling with the proliferation marker Ki67 
increased in parallel with BMDC accumulation within the CNS. Our results indicate that 
establishment of high levels of blood and BM chimerism alone is not sufficient to induce 
BMDC accumulation within the CNS and that CNS conditioning is a crucial requirement 
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inTrODUcTiOn
Following bone marrow (BM) transplantation (BMT), donor 
BM-derived cells (BMDCs) can migrate to various sites in the 
recipient including the BM and the central nervous system (CNS) 
(1). It is generally believed that the BMDCs that accumulate 
within the CNS are predominantly of monocytic lineage (2–4). 
These BM-derived monocytic lineage cells integrate within the 
CNS, exhibit several microglial markers, and have morphologies 
reminiscent of endogenous microglia and perivascular mac-
rophages associated with blood vessels (2). Recent studies have 
shown that some populations of macrophages at CNS interfaces, 
such as perivascular macrophages, have stable populations and 
do not necessarily derive from BMDCs (5).
For successful BMT, niche space must be generated within the 
recipient BM compartment to allow for donor cell engraftment. 
While this is most commonly achieved using myeloablative irra-
diation, this procedure can lead to lethal damage and inflamma-
tion in the CNS as well as immunosuppression that increases the 
potential for secondary infections (6). Consequently, a number 
of recent reports have explored the utility of non-irradiative 
conditioning protocols. Busulfan (BU) is a clinically approved 
bifunctional alkylating agent that depletes non-cycling primitive 
stem cells in the BM and has weak immunosuppressive properties 
(7). We and others have found that conditioning with BU prior 
to BMT leads to high levels of BM chimerism and accumulation 
of BMDCs within the CNS (2–4, 8–12). In fact, Wilkinson et al. 
have claimed that BU conditioning enhances engraftment of 
BMDCs compared to whole-body lethal irradiation when using 
a higher dose of BU (125 mg/kg), than we and others have used 
previously (4).
The microglial population is established by primitive mye-
loid cells during embryogenesis and is largely self-sustaining 
in the adult CNS (13). In parabiotic models where chimerism 
is established physiologically by surgically connecting the cir-
culations of two mice, rather than by injecting whole BM into 
the circulation, accumulation of donor BMDCs in the CNS 
does not occur even after irradiation of the parabiotic recipient 
(14). Similarly, transplantation of BMDCs following whole-
body irradiation does not lead to accumulation of BMDCs in 
the CNS if the brain is protected by shielding, demonstrating 
the importance of brain conditioning for BMDC accumula-
tion to occur in the CNS (15). Together, these observations 
suggest that reconstitution of the CNS with BMDCs requires 
both the presence of monocytic lineage progenitors in the 
blood circulation capable of efficient transmigration across 
the blood–brain barrier (BBB), and conditioning of the BBB/
CNS, possibly through ablation of endogenous proliferating 
microglia (8).
Given the potential utility of BMDCs as a vehicle to deliver 
therapeutics to the CNS, we sought to further elucidate the 
mechanisms involved in BMDC accumulation within the CNS 
of a mouse model of amyotrophic lateral sclerosis (ALS). ALS is 
a neurogenerative disease characterized by the progressive loss of 
motoneurons in the brainstem and spinal cord, as well as neuron 
loss in the cerebrum. ALS pathogenesis is heterogeneous and is 
associated with mutations in several genes, as well as with other 
pathological processes including excitotoxicity, oxidative injury, 
protein aggregation, and altered RNA metabolism that result 
in cellular dysfunction (16). The gene mutations found in ALS 
include those for Cu/Zn superoxide dismutase (SOD1), which 
subsequently led to the development of transgenic mice over-
expressing human mutant SOD1 (mSOD) as a murine model of 
ALS (17). The G93A mSOD transgenic model develops progres-
sive motoneuron degeneration and limb paralysis mimicking 
human ALS.
Regardless of the initiating causes of ALS, pathologically ALS 
is characterized by activation and proliferation of microglia, in 
addition to the neuron loss, suggesting that microglia contrib-
ute to ALS pathogenesis (16). Recent work has claimed that 
the increased number of monocyte lineage cells found in the 
spinal cords of mSOD mice, and possibly ALS patients, is due 
to recruitment of circulating Ly6Chi monocytes (18). Butovsky 
and colleagues reported that recruited Ly6Chi monocytes were 
detected in the spinal cord early in disease and that the number 
of Ly6Chi cells increased as disease progressed, reflecting further 
recruitment of monocytes. By contrast, the population of resident 
microglia, identified using the marker CD39, decreased with 
disease progression (18). Use of anti-Ly6C monoclonal antibody 
against infiltrating monocytes slowed disease progression, pre-
sumably by decreasing the entry of recruited Ly6C monocytes 
to the spinal cord (18). However, using RNA sequencing and 
evaluation of specific expression patterns of spinal cord microglia 
and peripheral monocytes, Chiu et al. found resident microglia 
increased in number during disease progression, but that the 
monocyte population did not increase, unlike the results of 
Butovsky et  al. (19). Furthermore, Chiu et  al. did not observe 
many Ly6Chi cells in spinal cord, suggesting limited infiltration 
of peripheral monocytes (19). In previous studies where we 
generated parabiotic mice pairs using wild-type (WT) mice 
ubiquitously expressing green fluorescent protein (GFP) and 
mSOD mice, we did not observe any entry of GFP+ cells from 
the parabiont into the CNS of the mSOD mouse, suggesting that 
there is no infiltration of monocytes into the CNS of mSOD mice 
under physiological conditions (14). Notably, parabiosis cannot 
be maintained when the mSOD mouse becomes very debilitated, 
limiting the evaluation of peripheral monocyte recruitment in 
late diseases stages.
for BMDC accumulation to occur. Moreover, it appears that proliferation of BMDCs that 
infiltrate the CNS is partly responsible for cell accumulation in busulfan-conditioned ALS 
mice.
Keywords: busulfan, treosulfan, amyotrophic lateral sclerosis, bone marrow-derived cells, monocyte, granulocyte 
colony-stimulating factor, aMD3100, central nervous system
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In the present study, we transplanted donor BM cells isolated 
from mice ubiquitously expressing GFP in order to monitor and 
characterize BMDC accumulation in BU-conditioned mice. Using 
this transplantation model, we evaluated the effects that different 
doses of BU had on BMDC accumulation within the CNS. The 
current literature suggests that both circulating progenitors and 
CNS conditioning are required for BMDC accumulation within 
the CNS. As such, we also monitored the effects of pharmacologi-
cal mobilization of BMDCs, and the consequences of minimizing 
CNS conditioning by using the BU analog treosulfan (TREO), on 
BMDC accumulation within the CNS. We had three hypotheses; 
we expected that BMDC accumulation would be dependent on 
the conditioning method and that BMDC accumulation in the 
spinal cord would increase with time, consequent to the prolifera-
tion of the BMDC within the CNS. We also hypothesized that 
mobilization of BMDC from BM would increase the number of 
monocyte lineage cells entering the spinal cord and contributing 
to BMDC accumulation.
MaTerials anD MeThODs
ethics statement
All protocols related to the use of animals in this study were 
reviewed and approved by the University Animal Care Committee 
of Simon Fraser University and were in compliance with the 
Canadian Council of Animal Care, the NIH Guide for the Care 
and Use of Laboratory Animals, and the EEC Council Directive.
animals
A colony of transgenic mice that over-express mutant human super-
oxide dismutase-1 (mSOD; B6.Cg-Tg(SOD1*G93A)1Gur/J; Jax 
004435) was established at Simon Fraser University using breed-
ing pairs obtained from Jackson Laboratories (Bar Harbor, ME, 
USA). The mice were maintained under temperature-controlled 
conditions with a 12-h light:12-h dark cycle, and were supplied 
with food and water ad libitum. As mSOD+ females are unable 
to successfully breed, WT females (C57BL/6J; Jax 000664) were 
paired with mSOD+ males. Genotypes of mice were determined 
by PCR analysis of genomic DNA isolated from ear tissue col-
lected during notching as described previously (17). The mSOD 
mice develop progressive motoneuron degeneration, culminat-
ing in muscle atrophy and eventually hind limb paralysis. Unless 
otherwise stated, mSOD mice, as well as age- and sex-matched 
controls, were collected at advanced stage of disease progression 
defined as >5 s to right from lateral recumbency.
Donor mice ubiquitously expressing GFP under the control 
of the β-actin promoter (C57BL/6; GFP/CD45.2) were obtained 
from Dr. I. Weissmann. Mice were bred and maintained as 
heterozygotes at Simon Fraser University, with genotypes being 
confirmed by observing GFP expression in collected ear tissue by 
fluorescence microscopy.
Myelosuppressive conditioning
The myelosuppressive dialkylating agent busulfan (Busulfex, 
Otsuka Pharmaceuticals, Japan) was diluted from pharmaceuti-
cal stock solution to 3  mg/mL with sterile PBS just prior to 
administration. Fractionated doses of 20 mg/kg/day of BU were 
administered via intraperitoneal injections until a total dose of 
60–100 mg/kg was delivered as we have done previously (3, 11, 
12). For a total dose of 125 mg/kg, fractionated doses of 25 mg/
kg/day were administered for 5 days (4). BMTs were conducted 
24 h following the final injection of BU.
Treosulfan (TREO; Medac, DE), a hydrophilic analog of BU 
that does not readily cross the BBB (20, 21), was resuspended in 
sterile ddH2O at a concentration of 50 mg/mL just prior to admin-
istration. Doses were selected based upon previous studies by Van 
Pel et al. and Nasa et al. (22, 23). Mice conditioned with 4,500 mg/
kg TREO received daily intraperitoneal injections of 1,500 mg/
kg/day over the course of 3  days while mice conditioned with 
6,000  mg/kg TREO received daily intraperitoneal injections of 
2,000 mg/kg/day over the course of 3 days. BMTs were conducted 
72 h following the final injection of TREO as evidence suggests 
this improves grafting efficiency (23).
Bone Marrow Transplantation
Bone marrow cells were isolated from the femurs and tibiae 
of GFP+ donor mice. Briefly, donors were euthanized, and the 
femurs/tibiae were removed and cleaned of tissue. The end caps 
were shaved off the bones, and BM cells were isolated by flushing 
the medullary cavity with sterile PBS. Red blood cells were lysed 
with ACK lysing buffer (A10492-01, Life Technologies), and the 
BM cells were resuspended in sterile PBS at a final concentration 
of 5 × 106 cells/mL. Three hundred microliters of cell suspension 
was injected via the tail vein into conditioned recipients. Details 
of the BMT procedure are described elsewhere (11).
Measuring extent of chimerism
In order to estimate the extent of BM chimerism, blood was sam-
pled from the saphenous vein and red blood cells were lysed with 
ACK lysing buffer. Myeloid cells were labeled with anti-CD11b-
APC (1:400; 17-0112-81, eBioscience) and anti-GR1-APC (1:400; 
553129, BD Pharmingen) antibodies, while lymphoid cells were 
labeled with anti-CD3e-PECy7 (1:200; 25-0031-81, eBioscience) 
and anti-CD45R-PECy7 (1:200; 25-0452-81, eBioscience) anti-
bodies. Cells were quantified by flow cytometry using a Guava 
flow cytometer (EMD Millipore, DE, USA) and analyzed using 
FlowJo (FlowJo, Ashland, OR, USA).
During tissue collection, a single femur was removed following 
perfusion with PBS and prior to fixation with paraformaldehyde. 
BM cells were flushed from the femur using FACS buffer (2mM 
EDTA + 2% fetal bovine serum in PBS) and subsequently pro-
cessed in a similar fashion as blood samples above.
Mobilization experiments
Bone marrow cells were mobilized into the circulation using 
either granulocyte colony-stimulating factor (GCSF), AMD3100 
(plerixafor), or a combination of GCSF and AMD3100. For 
GCSF-mediated mobilization, GCSF [Neupogen (filgrastim), 
Amgen, Thousand Oaks, CA, USA] was diluted from the phar-
maceutical stock to 30 μg/mL with sterile PBS + 0.1% BSA, and 
mice received daily intraperitoneal injections of 300 μg/kg GCSF 
for five consecutive days (24). For AMD3100-mediated mobiliza-
tion, AMD3100 octahydrochloride hydrate (A5602, Sigma) was 
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resuspended to 0.5 mg/mL with sterile PBS, and mice received a 
single intraperitoneal injection of 5 mg/kg AMD3100 (25, 26). 
To combine mobilization treatments, mice received daily intra-
peritoneal injections of 300 μg/kg GCSF for 4 days followed by 
a single intraperitoneal injection of 5 mg/kg AMD3100 on day 5 
(25, 26).
Tissue collection and Processing
Tissue was collected as previously described (27). Briefly, mice 
were euthanized and transcardially perfused with 30 mL of PBS. 
The femur was removed to determine chimerism, and subse-
quently, the mice were perfused with 30 mL of 4% paraformalde-
hyde (w/v). Spinal columns were dissected and post-fixed in 4% 
paraformaldehyde at 4°C overnight. The spinal cord was removed 
from the spinal column, and the tissue was then cryoprotected in 
20% sucrose (w/v) for 24–72 h at 4°C. Tissue was then embedded 
in TissueTek OCT embedding compound (Sakura Finetek, USA), 
wrapped in parafilm, and stored at −80°C. Tissue was processed 
for immunohistochemistry as described previously (27). Briefly, 
30 μm sections of lumbar region of the spinal cord were sectioned 
on a cryostat and every fifth section was collected, with at least 10 
sections per sample. Samples were stored in DeOlmos solution at 
−20°C until immunohistochemical staining was performed.
assessment of cell Proliferation
The cell proliferation-associated protein Ki67 was detected 
with anti-Ki67 antibody (1:1,000; ab15580, Abcam) using the 
free-floating immunohistochemistry procedure (2). Sections 
were mounted on slides using Vectashield mounting medium 
(Vector Labs, Burlingame, CA, USA), and proliferating cells 
were quantified in three individual lumbar spinal cord sections 
separated by at least 150 μm using a Leica epifluorescence micro-
scope. EdU (5-ethynyl-2′-deoxyuridine; A10044, Thermo Fisher 
Scientific) was resuspended at a concentration of 5 mg/mL and 
administered to mice via intraperitoneal injections of 50 mg/kg 
EdU 48 and 24 h prior to tissue collection. Incorporation of EdU 
into proliferating cells was quantified using the Click-iT EdU 
Imaging Kit (C10640, Thermo Fisher Scientific) according to the 
manufacturer’s instructions. Iba1 (1:1,000, 019-19741, Wako) was 
labeled using the free-floating immunohistochemistry procedure 
(2), and Iba1+ cells were quantified in one half of three individual 
lumbar spinal cord sections separated by at least 150 μm using a 
Leica epifluorescence microscope.
BMDc Quantification and Morphological 
analysis
Spinal cord sections were mounted on slides using Vectashield 
mounting medium and analyzed using a Leica epifluorescence 
microscope. GFP+ cells were quantified in five individual lumbar 
spinal cord sections separated by at least 150 μm as we have done 
previously (2, 3, 12, 27). The morphology of the GFP+ cells was 
classified according to Vallières and Sawchenko (28). Briefly, 
“round cells” were round in shape with a diameter <9 μm; “rod 
cells” were oblong in shape with rounded ends and a length of 
~20 μm; “elongated cells” had a length >20 μm without rounded 
ends; “ameboid” cells had a variable shape with a diameter 
>9 μm; and “stellate cells” had a small cell body and the presence 
of multiple ramified processes.
statistical Methods
All of the statistical analysis related to cell proliferation were 
carried out using SAS statistical software (version 9.4; SAS 
Canada, Toronto, ON, Canada). Analysis of GFP+ cell numbers 
and count data was used to compare the mean responses between 
treatments over time. The effects of treatment, time, and their 
two-way interaction were considered to be fixed effects in the 
model. Post hoc tests using the Tukey–Kramer method were used 
to locate differences in mean responses between pairs of treat-
ments and/or timepoints. All of the model diagnostics relating to 
the residuals were verified. In cases where the residuals failed to 
satisfy the model assumptions, a natural logarithm transforma-
tion was used. Statistical analyses of cell accumulation data were 
conducted using SPSS software.
resUlTs
BMDcs accumulate within the lumbar 
spinal cord of BU-conditioned Mice in a 
Time-, Dose-, and Disease-Dependent 
Manner
We have previously shown that myelosuppressive condition-
ing with 60–100  mg/kg BU, followed by BMT, was sufficient 
to generate mice with >80% BM chimerism after 11  weeks 
post-transplant (3). When mice are conditioned with 125  mg/
kg BU, chimerism was rapidly established during the first few 
weeks post-BMT and a high degree of chimerism is maintained 
over the subsequent weeks in the blood (Figure 1A). The high 
level of chimerism achieved was stable, being maintained in the 
blood and BM of BU-conditioned WT mice for at least 1 year 
post-BMT (Figure 1B). Notably, there were no differences in the 
levels of chimerism achieved in the blood and BM with any of 
the concentrations of BU used to condition the mice (Figure 1B).
Conditioning with 60–100 mg/kg BU allowed for accumula-
tion of transplanted BMDCs within the lumbar spinal cord of 
WT mice (Figure  2). BMDC accumulation increased with BU 
dosage, whereas accumulation was absent in mice conditioned 
with vehicle (Figure 2A). Similarly, BMDCs accumulated within 
the lumbar spinal cord of BU-conditioned WT mice in a time-
dependent manner for at least 1  year post-BMT (Figure  2B). 
Mice over-expressing mutant human Cu/Zn superoxide dis-
mutase-1 (mSOD) are the most commonly used mouse model of 
ALS, recapitulating many features of the human disease including 
neuroinflammation and microgliosis (17). BU conditioning led to 
a much greater accumulation of BMDCs within the lumbar spinal 
cord of mSOD mice compared to controls, particularly when 
mice were conditioned with 125 mg/kg BU (Figure 3; Table 1). 
As BU-conditioned mSOD and WT mice had comparable levels 
of BM chimerism, this suggests that ALS disease-related signals 
enhance BMDC accumulation within the CNS.
FigUre 2 | Bone marrow-derived cells accumulate in the lumbar 
spinal cord of BU-conditioned mice in a time- and dose-dependent 
manner. (a) Quantification of GFP+ donor cells within the lumbar spinal cord 
1 year post-bone marrow transplantation (BMT) in wild-type (WT) mice 
conditioned with the indicated dose of BU (milligrams per kilogram).  
(B) Quantification of GFP+ donor cells within the lumbar spinal cord in WT 
mice conditioned with 80 mg/kg of BU and collected at the indicated times 
post-BMT. Data = mean ± SEM for n = 3 mice/group; data were analyzed by 
ANOVA with p < 0.05.
FigUre 1 | high levels of chimerism are rapidly established and 
sustained in BU-conditioned mice. (a) Weekly flow cytometric 
quantification of GFP+ cells within the blood in mutant SOD1 mice 
conditioned with 125 mg/kg of BU and transplanted with GFP+ donor bone 
marrow (BM) cells. (B) Flow cytometric quantification of GFP+ cells within the 
blood and BM 1-year post-bone marrow transplantation in wild-type mice 
conditioned with the indicated dose of BU. Data = mean ± SEM for n = 3 
mice.
5
Peake et al. BMDC Accumulation in Murine ALS
Frontiers in Neurology | www.frontiersin.org March 2017 | Volume 8 | Article 75
The morphology of BMDCs can provide insight into both 
the localization and activation state of the cells. Morphologies 
were determined according to the criteria outlined by Vallières 
and Sawchenko, whereby cells were classified as being round, 
rod, elongated, ameboid, or stellate (28). Generally, cells with 
stellate and ameboid morphologies are parenchymal in localiza-
tion while round, rod, and elongated cells are usually located 
in perivascular regions (28). Very few parenchymal cells were 
detectable in BU-conditioned WT mice, even when 125 mg/kg 
was used, suggesting that few cells were able to actually infiltrate 
the CNS under these conditions (Table 1; Figure 3). Conversely, 
BU conditioning of mSOD mice led to significantly more BMDC 
accumulation within the lumbar spinal cord. This was particularly 
evident when 125 mg/kg BU was used, leading to >50% of the 
BMDCs accumulating within the lumbar spinal cord exhibiting 
morphologies that suggest parenchymal localization, with stellate 
cells being most prevalent (>40%; Table 1; Figure 3). Virtually all 
of the GFP+ BMDCs labeled with Iba1 and CD169, with the only 
exceptions being a small fraction of round/rod shaped cells (data 
not shown). These findings suggest that disease-related signals 
are required, along with BU conditioning, in order for BMDCs to 
gain access and accumulate within the CNS parenchyma rather 
than in perivascular locations.
a high level of chimerism alone is not 
sufficient to Produce BMDc accumulation 
within the lumbar spinal cord of msOD 
Mice
Doses of 60–125 mg/kg BU all led to similar levels of blood and 
BM chimerism, whereas the extent of BMDC accumulation 
within the lumbar spinal cord was different, suggesting that 
a high degree of chimerism alone is not sufficient to result in 
donor BMDC accumulation within the CNS, and that condition-
ing of the BBB/CNS is also necessary. To further explore this 
FigUre 3 | Bone marrow-derived cells accumulate to a much greater extent in the lumbar spinal cord of BU-conditioned mutant sOD1 (msOD) mice 
compared to wild-type (WT) controls. Immunohistochemical analysis of lumbar spinal cord sections from late stage mSOD mice and age-matched WT controls 
that were conditioned with 125 mg/kg BU and transplanted with GFP+ donor bone marrow cells at 6–8 weeks of age. GFP+ BMDCs are shown in green. Results are 
representative images from n ≥ 3 mice.
TaBle 1 | Quantification of gFP+ donor cells within the lumbar region of the spinal cord in late stage mutant sOD1 (msOD) mice and age-matched wild-
type (WT) controls transplanted with gFP+ donor bone marrow cells at 6–8 weeks of age.
gFP+ cells/lumbar spinal section
Treatment group Total round rod elongated ameboid stellate
80 mg/kg BU WT (n = 3) 4.5 ± 1.0 1.4 ± 0.3 (31.1%) 1.2 ± 0.3 (26.7%) 1.3 ± 0.3 (28.1%) 0.4 ± 0.0 (8.9%) 0.2 ± 0.1 (4.4%)
80 mg/kg BU mSOD (n = 3) 55.1 ± 10.7 15.0 ± 4.0 (27.2%) 7.3 ± 0.7 (13.2%) 19.9 ± 3.4 (36.2%) 5.4 ± 1.9 (9.8%) 7.5 ± 1.1 (13.7%)
125 mg/kg BU WT (n = 5) 12.5 ± 1.5 1.1 ± 0.3 (8.6%) 5.2 ± 0.7 (41.3%) 5.9 ± 1.0 (47.0%) 0.0 ± 0.0 (0.0%) 0.4 ± 0.1 (2.9%)
125 mg/kg BU mSOD (n = 4) 117.9 ± 9.1 3.4 ± 0.4 (2.9%) 25.3 ± 2.3 (21.5%) 25.6 ± 2.5 (21.7%) 13.1 ± 0.4 (11.1%) 50.5 ± 3.8 (42.8%)
6,000 mg/kg TREO WT (n = 3) 4.7 ± 0.4 1.6 ± 0.3 (34.0%) 1.7 ± 0.3 (36.9%) 1.4 ± 0.5 (29.8%) 0.0 ± 0.0 (0.0%) 0.0 ± 0.0 (0.0%)
6,000 mg/kg TREO mSOD (n = 4) 17.0 ± 1.6 0.5 ± 0.2 (2.6%) 9.7 ± 0.7 (57.1%) 6.5 ± 0.9 (38.2%) 0.2 ± 0.1 (0.9%) 0.2 ± 0.1 (0.9%)
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possibility, we established BM chimerism in mice by condition-
ing with TREO, a hydrophilic analog of BU that does not readily 
cross the BBB and enter the CNS. Conditioning with 6,000 mg/
kg TREO generated a high level of chimerism comparable 
to that achieved with BU in both the blood and BM, whereas 
4,500 mg/kg TREO resulted in a high level of chimerism in the 
blood but significantly lower levels of chimerism in the BM 
(Figure  4). Interestingly, TREO conditioning resulted in low 
levels of BMDC accumulation within the lumbar spinal cord of 
mSOD mice that were comparable to the levels of BMDC accu-
mulation seen in the lumbar spinal cord of WT mice conditioned 
with BU (Table 1). Moreover, few stellate and ameboid BMDCs 
were detectable in the CNS of TREO-conditioned mice, suggest-
ing that the majority of GFP+ cells were not localized within the 
CNS parenchyma.
Mobilization of BM cells into the 
circulation Does not increase gFP+ 
BMDc accumulation within the lumbar 
spinal cord
Work by Ajami et  al. using parabiotic mice suggests that the 
BM  cell type(s) capable of entering the CNS following condi-
tioning and BMT are primitive cells typically restricted to the 
BM (14). Under physiological conditions, primitive BM  cells/
progenitors are retained within the BM by stromal cell-derived 
factor-1 (SDF1), a chemokine with chemoattractant properties 
for hematopoietic cells expressing the complementary receptor 
CXCR4 (29). BMDCs were transiently mobilized from the BM 
into the circulation using either GCSF, a cytokine frequently 
used clinically to indirectly disrupt SDF1–CXCR4 binding, or 
FigUre 4 | high levels of blood and bone marrow (BM) chimerism are 
achieved in TreO-conditioned mice. Flow cytometric quantification of 
GFP+ cells within the blood and BM in late stage mutant SOD1 mice that 
were conditioned with 4,500 or 6,000 mg/kg TREO and transplanted with 
GFP+ donor BM cells at 6–8 weeks of age. Data = mean ± SEM for n ≥ 3 
mice/group; data were analyzed by a Student’s t-test with p < 0.05.
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plerixafor (AMD3100), a small molecule that directly inhibits the 
SDF1–CXCR4 interaction (Figure 5A) (29).
To determine if mobilized BMDCs could accumulate in the 
CNS and increase GFP+ cell number, high levels of stable BM 
chimerism (>85% GFP+ cells) were established for 5  weeks in 
mice conditioned with 80 mg/kg BU. However, mobilization with 
either GCSF or AMD3100 did not increase GFP+ cell number 
within the lumbar spinal cord in late-stage mSOD mice and age-
matched WT controls (Figures 5B,C). We also co-administered 
GCSF and AMD3100, as gene expression analyses suggest 
that this combination mobilizes different cell types compared 
to single drug treatment (30). However, use of both drugs did 
not result in increased GFP+ number within the lumbar spinal 
cord in late-stage mSOD mice and age-matched WT controls 
(Figures 5B,C). As evidence suggests that BMDC accumulation 
within the CNS is dependent upon conditioning of the BBB/
CNS, we also performed experiments where cells were mobilized 
3 days post-BMT in mSOD mice (Figure 5D), a timepoint where 
we hypothesized that the effects of BBB/CNS conditioning would 
still be present. Even when BM  cells were pharmacologically 
mobilized at this early timepoint, there was no increase in the 
number of BMDCs accumulating in the lumbar spinal cord of 
treated mice (Figure 5D).
BMDcs accumulate in the cns More 
rapidly in Mice conditioned with higher 
Doses of BU
To better understand the kinetics of BMDC accumulation within 
the CNS, we conditioned 15-week-old recipient mSOD mice with 
either low dose (80 mg/kg) or high dose (125 mg/kg) BU prior to 
transplantation with GFP+ BM cells. Transplanted mice were col-
lected weekly, and the number of GFP+ BMDC cells accumulat-
ing within the lumbar spinal cord was quantified. During the first 
3 weeks post-BMT, very few cells were detectable in the lumbar 
region of the spinal cord, regardless of the BU dose used for condi-
tioning (Figure 6A). Moreover, the GFP+ cells that were detected 
were primarily rod shaped, with no stellate cells identified, sug-
gesting that these GFP+ BMDCs had not yet accumulated within 
the CNS parenchyma (Figures 6B,C). Interestingly, the number 
of GFP+ BMDCs accumulating within the lumbar spinal cord of 
mSOD mice conditioned with 80 mg/kg of BU remained low for 
7 weeks post-BMT and only showed a significant increase when 
the mice were approaching disease end stage 8 weeks post-BMT 
(Figure 6A). Conversely, the number of BMDCs accumulating 
within the lumbar region of the spinal cord in mice conditioned 
with 125  mg/kg BU showed significant increases at weeks 6–8 
post-transplant (Figure 6A). Importantly, a large proportion of 
these GFP+ BMDCs accumulating within the lumbar spinal cord 
had a stellate morphology (>50% of BMDCs at weeks 7 and 8 
post-BMT), suggesting that these cells were localized within the 
CNS parenchyma (Figure 6C).
BMDc accumulation within the lumbar 
spinal cord is Due in Part to local 
Proliferation
To determine whether the accumulation of BMDCs in the 
lumbar spinal cord was due to proliferation of the GFP+ BMDC 
population, we immunolabeled dividing cells with Ki67, a nuclear 
protein expressed during mitosis (31). In spinal cords from mice 
treated with 80 mg/kg BU, Ki67+ cells were all GFP−, except for 
rare GFP+Ki67+ cells, indicating that proliferation of the BMDC 
population was very limited at all timepoints between weeks 3 and 
7 post-transplant (Figure 6D). In spinal cords from the 125 mg/
kg BU group, there were small numbers of GFP+Ki67+ cells at all 
timepoints from 4 to 7 weeks post-transplant (Figure 6D). The 
number of GFP+Ki67+ cells increased significantly in weeks 6 and 
7 post-transplant, but cell numbers were small (approximately 
5 cells/spinal section; Figure 6D). Interestingly, the increase in 
GFP+Ki67+ cells paralleled the increase in BMDC accumulation 
within the lumbar spinal cord (Figures 6A,D). Moreover, many 
of the GFP+Ki67+ and GFP+EdU+ BMDCs in the lumbar spinal 
cord exhibited a stellate morphology (Figure  6F), suggesting 
these cells were located in the CNS parenchyma. By contrast, 
GFP-Ki67 cells were much more evident at all timepoints. These 
data demonstrate some proliferation of GFP+ cells in spinal cord 
conditioned with 125 mg/kg BU, but that the extent of prolifera-
tion of these BMDCs may be limited.
We also evaluated the numbers of Iba1+ cells in spinal cord 
for both the 80 and 125 mg/kg BU groups and found that cell 
numbers did not increase significantly between weeks 3 and 6 
(Figure 6E). At week 7, we found a significant increase in Iba1+ 
cells in the 125  mg/kg BU group, but not the 80  mg/kg mice 
(Figure 6E), suggesting that the more extensive conditioning of 
125 mg/kg BU may increase the Iba1 cell number. The majority 
of Iba1+ cells in the lumbar spinal cord of mice conditioned with 
125 mg/kg BU were GFP−, measuring 98.5, 91.5, and 72.2% at 
weeks 3, 5, and 7 post-transplant, respectively. While GFP+ cells 
comprised little of the Iba1+ population at weeks 3 and 5 post-
transplant (1.5 and 8.5%), by 7 weeks post-transplant GFP+ cells 
were 27.8% of the Iba1+ population.
FigUre 5 | Mobilization of bone marrow-derived cells (BMDcs) into the circulation does not increase BMDc accumulation within the lumbar spinal 
cord of mutant sOD1 (msOD) mice and wild-type (WT) controls. (a) Flow cytometric analysis of peripheral blood following mobilization treatments in WT mice. 
Results are representative images from n = 3 mice. (B) The 6- to 8-week-old WT mice were conditioned with 80 mg/kg of BU and transplanted with GFP+ donor 
bone marrow (BM) cells. Chimerism was allowed to establish for 5 weeks prior to mobilization treatment. GFP+ cells were quantified in lumbar spinal cord sections at 
the indicated timepoints. Data = mean ± SEM for n ≥ 3 mice/treatment. (c,D) The 6- to 8-week-old mSOD mice were conditioned with 80 mg/kg of BU and 
transplanted with GFP+ donor BM cells. Chimerism was allowed to establish for 5 weeks (c) or 3 days (D) prior to mobilization treatment. GFP+ cells were quantified 
in lumbar spinal cord sections at disease end stage. Data = mean ± SEM for n ≥ 4 mice/treatment.
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DiscUssiOn
conditioning with BU or TreO Produces 
high levels of stable BM chimerism
Establishment of BM chimerism in animals has typically been 
achieved using myeloablative doses of irradiation. However, 
irradiation can lead to secondary complications and alternative 
approaches to achieving adequate conditioning for BMT have 
thus been explored (1). We have previously shown that a high 
degree of BM chimerism can be achieved using myelosuppressive 
conditioning with the chemotherapeutic molecule BU (3, 11, 12), 
and these results are supported by several other laboratories (4, 
8–10). Consistent with these findings, we have now shown that 
conditioning with a higher dose of BU (125 mg/kg) followed by 
BMT leads to rapid establishment of chimerism exceeding 90% in 
the BM of recipient mice. Moreover, the BM chimerism achieved 
using BU conditioning is stable, with high levels maintained for at 
least 1 year post-BMT. Similarly, conditioning with the BU analog 
TREO (6,000 mg/kg) produces a high degree of BM chimerism 
in mice comparable to BU (Figure 4). Our findings are similar 
to those of Van Pel et al. and Nasa et al., who have shown that 
concentrations of TREO ≤4,500 mg/kg result in lower, variable 
levels of chimerism, while 6,000 mg/kg TREO resulted in chimer-
ism of ~80% (22, 23).
These levels of chimerism were achieved when using syngeneic 
recipients. However, when recipients are not syngeneic, modifica-
tions of this conditioning protocol may be needed. For example, in 
a recent study evaluating the accumulation of BMDCs in the CNS 
of a murine model of Alzheimer’s disease (AD), we transplanted 
C57BL/6 GFP+ BM into mice having a mixed 129/C57Bl/6 
background. No sustained chimerism was achieved unless anti-
asialo ganglio-N-tetraosylceramide antibody was used to deplete 
FigUre 6 | Bone marrow-derived cells accumulate more rapidly and to a greater extent in mutant sOD1 (msOD) mice conditioned with a high dose 
of BU compared to a lower dose. (a) Weekly quantification of GFP+ cells within the lumbar spinal cord in mSOD mice conditioned with either 80 or 125 mg/kg 
BU and transplanted at 15 weeks of age. Data = mean ± SEM for n = 3 mice/timepoint. (B) Weekly quantification of GFP+ cell morphology within the lumbar spinal 
cord in mSOD mice conditioned with 80 mg/kg BU and transplanted at 15 weeks of age. Data = mean ± SEM for n = 3 mice/timepoint. (c) Weekly quantification of 
GFP+ cell morphology within the lumbar spinal cord in mSOD mice conditioned with 125 mg/kg BU and transplanted at 15 weeks of age. Data = mean ± SEM for 
n = 3 mice/timepoint. (D) Weekly quantification of Ki67+ cells and GFP+Ki67+ cells within the lumbar spinal cord in mSOD mice conditioned with either 80 or 
125 mg/kg BU and transplanted at 15 weeks of age. Data = mean ± SEM for n = 3 mice/timepoint. (e) Weekly quantification of Iba1+ cells within the lumbar spinal 
cord in mSOD mice conditioned with either 80 or 125 mg/kg BU and transplanted at 15 weeks of age. Data = mean ± SEM for n = 3 mice/timepoint.  
(F) Immunohistochemical analysis of lumbar spinal cord sections from late stage mSOD mice that were conditioned with 125 mg/kg BU and transplanted with GFP+ 
donor BM cells at 15 weeks of age. Mice were given IP injections of 50 mg/kg 5-ethynyl-2′-deoxyuridine (EdU) 48 and 24 h prior to collection to label proliferating 
cells. Nuclei are shown in blue, EdU in red, and GFP+ cells in green. Results are representative images from n = 3 mice. Data were analyzed by ANOVA, and 
post hoc tests using the Tukey–Kramer method were used. * represents a significant difference between 80 and 125 mg/kg treatment groups with p < 0.01; ŧ 
represents a significant difference from the preceding timepoint with p < 0.01; Ŧ represents a significant difference from the preceding timepoint with p = 0.02.
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natural killer cell activity, likely due to “hybrid resistance” caused 
by autoreactive natural killer cells from the mixed background 
recipient being directed to the transplanted BM (12). With BMT 
into syngeneic mice, no graft rejection was observed.
cns conditioning is required for BMDc 
accumulation within the cns
High levels of BM chimerism (>85%) were achieved using BU 
doses of 60–125  mg/kg. However, despite having comparable 
levels of chimerism, BMDCs accumulated within the lumbar spi-
nal cord in a dose-dependent manner. These results indicate that 
establishment of high levels of chimerism alone does not result 
in the accumulation of BMDCs within the CNS. In addition, 
when high levels of BM chimerism were achieved using TREO, 
low numbers of BMDCs were detectable within the lumbar spinal 
cord. Based upon its hydrophilicity, TREO would not be predicted 
to readily cross the BBB and gain access to the CNS. In support 
of this claim, little penetrance of TREO and its active metabolites 
were detectable within the CNS of rats administered 500 mg/kg 
TREO, and limited amounts of TREO crossed an in vitro BBB 
model (20, 21). Virtually, all of the BMDCs detectable in TREO-
conditioned mice had morphologies suggesting blood vessel-
associated localizations (Table  1). The very small proportion 
of the BMDCs with stellate or ameboid morphologies detected 
within the lumbar spinal cord of TREO-conditioned mice (<2%) 
is likely due to limited TREO penetration of the BBB and CNS 
conditioning. These results suggest that some degree of BBB dis-
ruption and/or CNS conditioning also likely needs to be present, 
either by irradiation or chemotherapy. BU has been shown to 
cross the BBB (~20% of a dose administered in humans) (32), and 
evidence suggests that the BBB is not obviously disrupted by BU 
conditioning (10). In crossing the BBB, BU may be creating niche 
space within the microglial compartment allowing for BMDCs to 
infiltrate the CNS and accumulate (8). Alternatively, as high doses 
of BU have been shown to have neurotoxic effects in patients 
and animals (33), it is also possible that BU is causing neuronal 
damage, which in turn increases BMDC accumulation through 
increased recruitment of BMDCs from the circulation and/or 
stimulating local BMDC proliferation within the CNS. Unlike the 
findings of Butovsky et al. (18), the present data indicate that in 
the absence of a CNS conditioning stimulus, there is limited entry 
and accumulation of BMDCs in the spinal cord, even in diseases 
such as murine ALS.
BMDc accumulation within the cns is 
Dependent on Disease-related 
Mechanisms
Small numbers of BMDCs were observed in WT mice conditioned 
with BU. Moreover, the morphology of BMDCs accumulating 
within the lumbar spinal cord of WT mice suggest that few, if 
any, of the cells were located within the CNS parenchyma. These 
GFP+ BMDCs were likely perivascular, even when 125 mg/kg BU 
was used. Recent studies by Wilkinson et al. found that 125 mg/
kg BU caused considerable accumulation of stellate BMDCs 
within the CNS of WT mice, an effect that was larger than that 
caused by myeloablative irradiation (4). Using the same dose of 
BU conditioning, we found substantially lower numbers of GFP+ 
BMDCs in the lumbar spinal cord and fewer GFP+ cells with a 
stellate morphology than Wilkinson and colleagues (Table  1). 
The differences we see in BMDC accumulation compared to 
Wilkinson et al. may be due to different CNS tissue being ana-
lyzed (brain vs spinal cord) or a slightly different transplantation 
procedures where we transplanted 10-fold less donor BMDCs (4).
As in many previous studies using both irradiative and 
non-irradiative conditioning, we find much larger numbers of 
BMDCs in the lumbar spinal cord of mSOD mice compared to 
WT mice, an effect that is also seen in other models of neuro-
degenerative disease (Table 1; Figure 3) (3, 11, 12). Stellate and 
ameboid cells generally constitute parenchymal cells within the 
CNS (28) and cells with these morphologies were frequently seen 
in mSOD mice, while very few were observed in WT mice, sug-
gesting that disease-related mechanisms were involved in BMDC 
accumulation within the CNS. Notably, the majority of BMDCs 
in the lumbar spinal cord of late stage mSOD mice conditioned 
with 125 mg/kg BU had a stellate morphology (Table 1), while 
our previous work using myeloablative irradiation showed the 
majority of cells to have an ameboid morphology (3). These dif-
ferences in BMDC morphology between irradiation and BU may 
be related to the cytokine profile triggered by the conditioning 
treatment (3).
From previous work, it is known that the BMDCs that accu-
mulate in the CNS are mostly monocytic lineage cells that express 
CX3CR1, although small numbers of T  lymphocytes may be 
present (2, 27, 34, 35). It is likely that endogenous microglia and 
monocyte-derived CNS macrophages constitute distinct popula-
tions with different functions (36, 37), but that the properties of 
these cell populations will differ in neurodegenerative disorders 
such as ALS or diseases with prominent inflammation, such as 
experimental autoimmune encephalitis (EAE). In EAE, mono-
cyte lineage cells efficiently enter the CNS and give rise to mature 
macrophages that seem indistinguishable morphologically from 
resident microglia (38). However, as recovery from the acute 
phase of EAE occurs, infiltrating monocyte lineage cells which 
had accumulated in the CNS undergo apoptosis (38). In contrast, 
the extent of BMDC accumulation in models of chronic neurode-
generative diseases such as ALS increases, likely due to expansion 
of accumulated BMDCs and possibly further BMDC entry. The 
factors responsible for BMDC entry include CCR2, as limited 
BMDC accumulation of BMDC occurs in CCR2−/− mice (38). 
Based upon work in EAE, it has been claimed that monocyte-
derived macrophages are phagocytic and inflammatory, whereas 
resident microglia have less inflammatory properties based on 
gene expression data (37). For instance, monocytes demonstrate 
an upregulation of CXCR2, CCR1, toll-like receptor 6, and other 
genes associated with inflammation, whereas microglia upregu-
late TNF, Stat1, and other genes associated with metabolism (37). 
It is likely that the method of chimerism used to achieve BMT 
in such studies will be relevant for the profile of gene expression 
observed. In mice transplanted using BU, elevations are seen 
in levels of serum and CNS G-CSF and IL-6 shortly following 
BMT, compared to irradiation (4). Monocyte lineage cells ulti-
mately derive from the monocyte/macrophage and dendritic cell 
precursor (MDP) (13). There is also evidence for a clonogenic 
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monocyte/macrophage restricted progenitor cell derived from 
the MDP termed the common monocyte progenitor (39) which 
could, in principle, be a cell type that accumulates in the CNS 
following BU administration and BMT.
Mobilization of BM cells into the 
circulation Does not increase BMDc 
accumulation in the cns
During BMT using whole or fractionated BM, BM cells includ-
ing progenitors are injected into the circulation of the recipient 
animal and may accumulate within the CNS. In an attempt to 
increase BMDC accumulation within the CNS, we mobilized 
cells from the BM using GCSF, AMD3100, or a combination of 
both treatments. Despite mobilizing BM  cells (Figure  5A), we 
were unable to increase the amount of BMDC accumulation in 
the lumbar spinal cord. It is possible that the BM cells mobilized 
by GCSF and AMD3100 were not capable of migrating into the 
CNS. Alternatively, BM  cells in the blood circulation may not 
have been mobilized for sufficient time, or in sufficient numbers 
to accumulate within the CNS. While there is evidence showing 
that GCSF can increase the number of BMDCs accumulating in 
the CNS of a mouse model of AD, these treatments were typi-
cally combined with other factors such as SDF-1, which would 
be expected to influence BMDC migration (26, 40). Furthermore, 
these experiments were performed in irradiated mice which may 
lead to different CNS/BBB conditioning that allows for the accu-
mulation of mobilized cells within the CNS. These observations 
have implications for the treatment of ALS. Previous studies have 
used GCSF treatment in ALS patients to produce BM mobiliza-
tion for collection and re-injected into patients to in an attempt 
to generate BMDC accumulation in the CNS (41, 42). However, 
given the present results, it remains doubtful as to whether GCSF 
treatment will alter BMDC accumulation in the CNS.
BMDc accumulation and Proliferation
The weekly analysis of BMDC accumulation within the lumbar 
spinal cord indicates that following myeloablation and chimer-
ism, only limited cell accumulation occurs for several weeks. A 
substantial increase in cell accumulation occurs only after the first 
5 weeks post-transplant in mSOD mice conditioned with 125 mg/
kg BU and after 7 weeks in mice conditioned with 80 mg/kg BU. 
This increase in cell number corresponds to a time when mice 
are developing neurological deficit, raising the possibility that the 
increased cell number occurs in relation to disease-related signals. 
It is well known that microglial proliferation occurs in mSOD mice 
(43). It is possible that the GFP+ BMDCs that seeded the CNS 
proliferate at a similar rate of expansion as endogenous microglia 
and that this expansion is responsible for some of the large num-
bers of GFP+ BMDCs seen, especially in mSOD mice at later times 
following transplantation (23). However, the present results show 
only small numbers of Ki67+GFP+ cells suggesting that in addition 
to cell proliferation, some entry of BMDCs likely occurs and that 
this entry is likely dependent on the conditioning stimulus.
It remains unclear to what extent BMDC accumulation within 
the CNS of BU-conditioned mice is due to proliferation compared 
to continued infiltration. In experiments using the proliferation 
markers EdU or Ki67, we found cell labeling of stellate GFP+ 
cells within the lumbar spinal cord. However, the number of 
cells labeled with these markers was small, consistent with the 
findings of Wilkinson et al. (4). As we only administered EdU for 
48 h prior to collecting tissue, it is unlikely that the cells divided 
in the BM and subsequently migrated into the lumbar spinal 
cord parenchyma. Moreover, several of the EdU-labeled cells 
we observed appeared to be actively dividing (Figure 6F), and 
Ki67 only labels cells that are proliferating. The limited numbers 
of cells labeled by EdU is likely a consequence of the short-time 
course that EdU can be administered to minimize the possibility 
of labeling proliferating within the BM that could subsequently 
infiltrate the lumbar spinal cord. Moreover, Ki67 only labels cells 
that are actively proliferating at the time of fixation and tissue 
collection. Thus, it is likely these techniques underestimate the 
extent that proliferation accounts for BMDC accumulation 
within the CNS.
cOnclUsiOn
The use of BMDCs in the therapy of CNS disease is in its infancy. 
To be clinically useful, BMDCs will need to be administered 
with conditioning agents that are mild enough to be tolerated, 
yet permit long-term BM chimerism. BU appears to be useful 
for this aim. Furthermore, this work and others have shown that 
high-level blood and BM chimerism are insufficient to ensure 
that large numbers of BMDCs will accumulate in the CNS. The 
results also show that substantially more BMDC accumulation 
can occur in a disease model than in WT animals, indicating 
that disease-related factors will influence BMDC entry, likely 
in a time-dependent manner. We do not find that mobilization 
of BM by GCSF or AMD3100 influences the extent of BMDC 
accumulation in CNS but suggests that BMDCs that accumulate 
in the CNS increase in number partially through proliferation.
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